Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in...

Area of Science:

• Cardiovascular Pharmacology
• Biochemistry
• Genetics

Background:

• Statins like atorvastatin and rosuvastatin are widely used to lower LDL cholesterol.
• Pleiotropic effects, beyond lipid lowering, may include antioxidant and anti-inflammatory actions.
• The lectin-like oxidized LDL receptor-1 (LOX-1) plays a role in oxidized LDL metabolism and vascular inflammation.

Purpose of the Study:

• To investigate the time-dependent effects of atorvastatin and rosuvastatin on oxidative stress and platelet activation.
• To determine if these effects are linked to LDL reduction or other pleiotropic actions.
• To assess the influence of LOX-1 3'UTR polymorphism on statin efficacy.

Main Methods:

• Sixty hypercholesterolemic subjects were randomized to atorvastatin 20mg or rosuvastatin 10mg daily.
• Participants were genotyped for the LOX-1 3'UTR polymorphism.
• Oxidative stress markers (8-iso-PGF2α), platelet activation (11-dehydro-TXB2), and hs-CRP were measured over 8 weeks.

Main Results:

• Both statins significantly reduced LDL cholesterol, hs-CRP, 8-iso-PGF2α, and 11-dehydro-TXB2 after 8 weeks.
• Reductions in these markers were comparable between atorvastatin and rosuvastatin groups.
• No significant differences in the impact of statins were observed based on LOX-1 haplotype, with LDL and CRP being independent predictors of 11-dehydro-TXB2 and LDL predicting 8-iso-PGF2α.

Conclusions:

• Atorvastatin and rosuvastatin demonstrate comparable efficacy in reducing inflammation, lipid peroxidation, and thromboxane-dependent platelet activation.
• The 3'UTR/LOX-1 polymorphism does not appear to modulate the observed effects of these statins.
• These findings suggest that the pleiotropic effects on oxidative stress and platelet activation are consistent across these statins, irrespective of specific genetic variations in LOX-1.